• 1
    Joyner MJ, Charkoudian N, Wallin BG. A sympathetic view of the sympathetic nervous system and human blood pressure regulation. Exp Physiol. 2008;93:715724.
  • 2
    Wallin BG, Charkoudian N. Sympathetic neural control of integrated cardiovascular function: insights from measurement of human sympathetic nerve activity. Muscle Nerve. 2007;36:595614.
  • 3
    Charkoudian N, Rabbitts JA. Sympathetic neural mechanisms in human cardiovascular health and disease. Mayo Clin Proc. 2009;84:822830.
  • 4
    Esler M. Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol. 2010;108:227237.
  • 5
    Grassi G, Seravalle G, Quarti-Trevano F. The ‘neuro-adrenergic’ hypothesis in hypertension. Current evidence. Exp Physiol. 2010;95:581586.
  • 6
    Fisher JP, Young CN, Fadel PJ. Central sympathetic overactivity: maladies and mechanisms. Auton Neurosci. 2009;148:515.
  • 7
    DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245R253.
  • 8
    Stadbauer V, Wright GA, Banaji M, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology. 2008;134:111119.
  • 9
    Campese VM, Ku E, Park J. Sympathetic renal innervation and resistant hypertension. Int J Hypertens. 2011;2011:814354.
  • 10
    DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289:R633R641.
  • 11
    Tsioufis C, Kordalis A, Flessas D, et al. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens. 2011;2011:642416.
  • 12
    Papademetriou V, Doumas M, Faselis C, et al. Carotid baroreceptor stimulation for the treatment of resistant hypertension. Int J Hypertens. 2011;2011:964394.
  • 13
    Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:12751281.
  • 14
    Symplicity HTN-2 Investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:19031909.
  • 15
    Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911917.
  • 16
    Krum H, Barman N, Schlaich M. Long-term follow-up of catheter-based renal sympathetic denervation for resistant hypertension confirms durable blood pressure reduction. J Am Coll Cardiol. 2012;59:E1704.
  • 17
    Brinkmann J, Heusser K, Schmidt BM, et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension. 2012;60:14851490.
  • 18
    Papademetriou V, Worthley S, Tsioufis C, et al. EnligHTN™ I, First-in-Human Multicenter Study of a Multi-Electrode Renal Denervation Catheter in Patients with Drug-Resistant Hypertension: Circulation (A) Presentation at 2012 scientific session-Special Sessions.